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Abstract  
Background: A significant proportion of screen-detected men with prostate cancer may be 
overdiagnosed. Active Surveillance (AS) has emerged as a way to mitigate this problem, by 
delaying treatment of men, who are at low-risk until this becomes necessary. However, it is not 
known after how much time or biopsy rounds should patients stop AS and transition to 
conservative management (CM), if no progression is detected.  
Methods: We used a microsimulation model with natural history of prostate cancer based on 
ERSPC and SEER data. We modeled referral to treatment while in AS, based on Johns Hopkins 
treatment-free survival data. We projected lifetime costs and effects of AS (including referral to 
treatment) under different biopsy follow-up schedules compared to CM, where radical treatment 
only occurs if the cancer becomes symptomatic (modelled as time of clinical diagnosis in 
absence of screening).  
Results: For men with low-risk disease in younger age groups (55-65), AS is cost-effective for 
up to 7 yearly biopsy rounds. For men older than 65, even one biopsy round results in quality 
adjusted life years (QALYs) lost, though it may result in QALYs gained for men without 
previous screening. For men with intermediate risk disease AS is cost-effective even for men in 
65-75 age group. 
Conclusion: The benefit of AS when compared to CM is strongly dependent on life expectancy 
and disease risk. Clinicians should take this into account when selecting men to AS, deciding on 
biopsy frequency and when to stop AS surveillance rounds and transition to CM.  
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Introduction 
Active Surveillance (AS) has emerged as a way to minimize overtreatment due to frequent PSA-
based prostate cancer screening. It consists on the monitoring of newly diagnosed and not yet 
treated men through PSA tests and/or repeat biopsies. The goal of AS is to delay or avoid radical 
treatment in patients who are unlikely to become symptomatic [1]. In the conservative 
management (CM) regimen patients are also monitored, although not with invasive procedures 
like, prostate biopsies, and without curative intent, unless the patient becomes symptomatic. It is 
similar to watchful waiting, though this term often refers only to older men, or with major 
comorbidities [1].  
The majority of clinical cohorts following men on AS  have a limited follow-up, which is not 
long enough to establish the long term effects [2-7], however there is an emerging consensus 
regarding the safety of AS for low-risk men [8-10], and the rate of low-risk men assigned to AS 
is increasing rapidly [11]. Still there is substantial uncertainty about what is the most optimal 
way of performing AS,  namely about whom to include and the follow-up protocol [8-10].   
Computer modelling has been used to make projections of the potential effects of AS on prostate 
cancer mortality (PCM) and overtreatment. Previous studies [12, 13] found that compared to 
immediate treatment, AS results in a modest increase in PCM (1.4% and 1.8%, respectively).  
Others [14-17] have compared the costs or cost-effectiveness of AS and/or CM to immediate 
treatment and found that AS seems to be more advantageous. As far as we know, no simulation 
study has tried to optimize the age to stop AS and start CM. 
There are virtually no clinical studies on when can a patient safely discontinue AS, if no 
progression is detected and stop being considered for radical treatment, which may potentially 
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lead to treatment decisions to depend on personal or physician’s preferences. In the PRIAS 
cohort, the compliance with PSA testing during AS was relatively high, however the compliance 
with prostate biopsies is relatively low and decreases rapidly over time from 81% at 1 year to 
33% after 10 years [18]. A recent study [19] using SEER data found that only 13% of men 
underwent prostate biopsy after 2 years, in a community setting. For older patients or men 
suffering from significant comorbidities, this is probably reasonable, however, for patients with a 
longer life expectancy there could be a danger of progression to advanced disease, due to non-
adherence to the biopsy protocol.  
The aim of this study is to determine at which age it is safe and more cost-effective to leave AS 
and transition to a CM context, for different age and disease risk groups. We use a previously 
validated [12, 20] microsimulation model of prostate cancer screening and AS, and compare the 
incremental cost-effectiveness of each additional AS biopsy round, compared to CM.  
Methods 
Simulation Model 
MISCAN is a microsimulation model designed to evaluate the lifetime effects of prostate cancer 
screening. A detailed description is available in the Supporting Information, in 
http://cisnet.cancer.gov/prostate/profiles.html and in previously published studies [12, 21].   
Men may experience onset of prostate cancer, based on a constant hazard per age group.  In each 
disease stage, a man may transition to a higher T-stage, a higher grade, become metastasized or 
clinical diagnosed. We modeled 18 health states corresponding to the combination of 3 stages 
(T1, T2 and T3), 3 grades (Gleason less than 7, 7, and more than 7) and whether or not cancer is 
metastasized. Additional states were created specifically to model AS. Men in T2-stage, Gleason 
6 were classified as T2a or T2bc and Gleason 7 men as classified as Gleason 3+4 or 4+3, 
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depending on their remaining lead-time (i.e. time to clinical diagnosis in absence of screening) 
and age group, based on ERSPC data. We also modeled PSA growth from onset until detection. 
The parameters of the natural history, which include onset of the disease, durations, transition 
probabilities between health states and PSA growth were calibrated to observed ERSPC’s  PSA 
distribution data and SEER incidence data [21, 22] (Supporting Information Figure S1).  
At clinical detection, a baseline survival is assigned, which depends on Gleason score ( < 8 or ≥ 
8) and was estimated based on SEER data from the pre-PSA era (1983-1986). This was adjusted, 
for improvements on survival not directly associated with screening or primary treatment, by 
adding a hazard ratio for prostate cancer survival of 0.82, which was calibrated to the observed 
PCM in the ERSPC control (no screening) group (Supporting Information Table S1).   
We add a benefit of treatment and a benefit of screening (in case the patient is screen-detected) 
to the baseline survival. The hazard ratio for the benefit of treatment equals 0.56 for radical 
prostatectomy [23]. For radiation therapy this equals 0.63 using the same rationale as in [24].  
The effect of screening is modelled through a lead-time dependent cure rate for non-metastatic 
cases, 
Cure probability =  exp(cure parameter * lead-time).   
The cure parameter was calibrated based on the observed prostate cancer mortality reduction due 
to screening in the ERSPC trial [25] (Supporting Information Table S1, Supporting Information 
Figure S2).  
When the patient is referred to AS, natural history progresses as if the patient was not screen-
detected. Referral to radical treatment may occur due to detection of Gleason or volume 
progression (which is assumed to occur after an increase in T-stage) at each biopsy round, due to 
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personal preference (randomly selected from all men in AS) or if the cancer becomes 
symptomatic, which we assume to occur at the time of clinical diagnosis  in absence screening 
(Table I, Figure 1). The probabilities of referral to radical treatment for low-risk men are 
estimated (given disease progression, which is based on our natural history model)  using JH-AS 
observed treatment-free survival data [4] (Supporting Information Table 2). For intermediate risk 
men, we assume that given the risk of progression (which is Gleason and T-stage dependent), the 
probabilities of referral to treatment are the same as for low-risk men.  
At the time of referral to treatment, survival differs compared to what would have happened if 
the patient would be treated at the time of screening diagnosis, by assuming a decrease in the 
benefit of screening, depending on the remaining lead-time for the patient.   
Active Surveillance 
We simulate a cohort of 10 million men, based on US lifetables. In the basecase, men are 
screened between 55 and the upper bound of the age group selected for AS (with an attendance 
rate of 90%), with a PSA threshold for biopsy referral of 4 and biopsy compliance equal to 41%, 
based on the PLCO trial [26]. Biopsy Compliance during AS is based on the PRIAS study [17] 
(Supporting Information Table S2). 
We follow men who are selected for AS in a particular age group (55-59, 60-64, 65-69, 70-74). 
Men selected for AS have either low risk (Gleason 6, <= T2 stage, PSA <10)  or intermediate 
risk (up to Gleason 3+4, T2 stage and PSA < 20) disease (Table I). We compare AS protocols 
differing by follow-up (1, 4, 7 and 10 biopsy rounds) and biopsy frequency (annual or triannual) 
with CM, where men are only treated, if in absence of screening, the patient would be clinical 
diagnosed (Figure 1).  
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Initially, the rate of clinical diagnosis in absence of screening was based on the control group  
and interval cancers in the screening group of the ERSPC trial. Since the model was adapted to 
US, an extra hazard of clinical diagnosis was added, reflecting an earlier probability of detection. 
This was calibrated to SEER incidence data from before the introduction of PSA-based 
screening.  
We assume that the main difference between AS and CM surveillance regimens is that AS 
includes prostate biopsies, i.e. we assume a similar rate of PSA tests or visits to the doctor 
between the two regimens. We also assume that the main driver of referral to treatment while in 
AS is the result of the prostate biopsy.  
Quality of Life and Costs  
QALYs were calculated by using utility estimates ranging between 0 (death or worst imaginable 
health) and 1 (pre-diagnosis health, which is assumed to be full health). Estimates for the utilities 
and its durations for all stages of AS, including, prostate biopsies, radical treatment, post-
recovery and palliative therapy are based on [27-29] (Table II). QALYs were calculated by 
multiplying the loss in utility with the duration of the phase and the number of men who 
experienced the event, as predicted by MISCAN.  
 
Costs of AS compared to CM include the cost of prostate biopsies and the extra cost of radical 
treatment, since in CM regimen only men who are clinically diagnosed are treated. The cost of 
immediate treatment is the average lifetime cost for men treated at age 65, including adverse 
events, indirect costs and post-treatment surveillance [30]. Costs of palliative therapy are based     
on [31]. All costs were inflated to 2015 US Dollars.   
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We calculate the cost per QALY using a 3% discount rate for all costs and effects. The most 
efficient AS policies are determined based on their incremental cost-effectiveness ratio (ICER). 
An AS protocol is considered to be cost-effective if its ICER is below $100,000. 
Outcomes 
We estimated the cost-effectiveness of each AS protocol compared to CM (no treatment) for men 
who are selected to AS. The main outcome is cost per QALY gained of the AS protocol 
compared to CM. Other important outcomes include overtreatment,  prostate cancer mortality, 
life years gained (LYG) and costs.  
 
Sensitivity Analyses 
We analyzed the effects of some plausible alternative scenarios. For the age groups 55-59 and 
60-64, we studied whether a lower biopsy frequency (triannual after the first year) or a higher 
biopsy compliance (81% for the whole follow-up) would have a large impact on QALYs gained. 
For the age group 65-69, we projected the effects of starting screening at age 65, and we split the 
age group in smaller intervals (65-66, 65-67, 65-68). In order to assess the effect of uncertainty 
around the parameter estimates on the outcomes, several multivariate sensitivity analyses were 
performed, including the utility and cost estimates for each event, the parameters of the model 
related to treatment benefit, the benefit due to early detection,  and the rate of clinical diagnosis.   
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Results 
Effects 
In figure 1, LYG compared to the CM situation are plotted against overtreated men per 1000. 
Both outcomes are highly dependent on the age group of selection for AS. In the age group 55-
59, performing 4 biopsy rounds results in 723 LYG at a cost of 120 overtreated men per 1000 
men in AS. By contrast, for the age group 70-74, 4 biopsy rounds result in only 98 LYG with 
224 overtreated men per 1000.  
In table III, all effects are shown, with QALYs and LYG discounted at 3%. AS results in life 
years gained for all age groups. However after adjusting life years for quality life, our model 
projects that for men older than 65, even one biopsy round results in QALYs lost, relative to CM 
situation. For men aged between 55-59 after 4 biopsy rounds, the model projects about 264 
QALYS gained and for men aged between 60-64, 118 QALYs gained.  
Costs 
In table III, the total cost of AS is shown. Cost of AS increases with number of biopsy rounds 
and age group. Cost varied between $0.9 million, per 1000 men in AS, for one biopsy for 55-59 
men and $8.2 million for men aged 70-74 after 10 biopsy rounds.  
Cost-Effectiveness 
We show the cost-effectiveness of AS compared to CM in table III. For low-risk men in age 
groups 65-69 and 70-74 AS is not effective. For men in age group 55-59, the estimated ICER 
after 10 yearly biopsy rounds (yearly biopsies) is $16,199. For the age group 60-64 the ICER is 
$113,909.  
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Other Scenarios 
Under the assumption that biopsy compliance during AS remains 81% for the whole follow-up 
(observed biopsy compliance in the first year of the PRIAS 14), we see that after 4 biopsy rounds 
QALYs gained increase from 264 to 300 for the 55-59 age group, and from 118 to 131  for the 
60-64 age group (Table IV). If the biopsy frequency becomes triannual after the first year, 
QALYs gained decrease from 264 to 163, for the 55-59 age group, and from 118 to 71 for the 
60-64 age group (Table IV). For men aged between 70-74 with intermediate-risk prostate cancer, 
AS may be cost-effective up to 7 biopsy rounds. For men aged 65-69 the ICER is only $21,299 
after 10 biopsy rounds. AS for low-risk men aged 65-69 may results in QALYs gained if 
screening only started at age 65 or if AS is restricted to men younger than 68 (Supporting 
Information Table 6).  
Sensitivity Analyses 
Our sensitivity analyses focus on the age group 60-65. At four biopsy rounds we find a range for 
the ICER between $15,842 (50% higher costs) and $78,709 (unfavorable utilities for prostate 
biopsies and treatment).  At seven biopsy rounds the ICER ranges between $20,329 and 
$217,517. Of all the sets of parameters considered, utilities have the largest effect on the cost per 
QALY (Supporting Information Table 7 and 8). The only scenario where AS after 7 biopsy 
rounds was not cost-effective was when we applied unfavorable utilities towards screening and 
treatment procedures. By contrast, if we would apply more favorable utilities, lower costs, lower 
treatment benefit and a higher rate of clinical diagnosis then AS would become cost-effective 
after 10 biopsy rounds (Supporting Information Table 7 and 8).  
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Discussion 
In this study we tried to determine for the first time, how much time should men stay on AS and 
be considered for treatment. Previous clinical studies have ascertained AS is relatively safe for 
low-risk men [2-7, 11, 12]. Additionally, most studies [14-17] found that AS is less expensive or 
cost-effective than immediate treatment. However, no clinical cohort or simulation study has 
examined how much time should men be on AS or how the age group or life expectancy could 
determine the intensity of the follow-up schedule.  
In this study we find that AS with 7 yearly biopsy rounds for low-risk men is cost-effective 
compared to CM, but only for age group 55-65 and for men up to age 75 with intermediate risk 
disease. We performed this by calculating the cost-effectiveness of AS with different follow-up 
biopsy schedules (1, 4, 7 and 10 yearly biopsy rounds) compared to a CM group where men can 
only be treated if their cancer becomes symptomatic (which is modelled as the time of clinical 
diagnosis in absence of screening).  
The inclusion of low-risk men younger than 60 in AS is not consensual [10]. These are the best 
candidates for immediate treatment and have a relatively low probability of being overtreated 
[32, 33]. We find that if these men are included on AS, they require an intensive yearly biopsy 
schedule, which should continue for at least 10 yearly biopsy rounds. A low biopsy compliance 
or biopsy frequency may result in QALYs lost and in a significant increase in PCM.  
By contrast, for men older than 70, AS is not cost-effective, and does not result in QALY’s  
gained, though some lives are saved. For men aged between 60-64, AS appears to be cost-
effective up to 7 biopsy rounds, and for men aged 65-69 AS results on QALYs lost. With a finer 
analysis, we find that for men aged 65-67, and for men who started screening after age 65 AS 
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results in QALYs gained but it is still not cost-effective. Just like for men younger than 60, 
selecting intermediate risk men for AS is still under debate [34]. We find that if these men are 
selected, an intensive AS regime with many follow-up biopsies is recommended (for men 
younger than 70, at least 10 yearly biopsy rounds). 
Sensitivity Analyses found that the results in this study are the most sensitive to the utilities. For 
instance, using more unfavorable utilities about biopsies and treatment made the ICER become 
higher than $100,000 at 7 years for the age group 60-65. However, there were more scenarios 
(higher cure rate, lower treatment effect, favorable utilities), where AS with 10 yearly biopsy 
rounds became cost-effective.  
This study is subject to some limitations. Our AS model uses a simplification of the criteria of 
selection for AS and to be referred to treatment compared to most clinical cohorts. For instance, 
we do not model the number of positive biopsy cores and we assume volume progression can 
only occur, if there is an increase in T-stage. The probabilities of referral to treatment are based 
on the JH cohort, which has slightly different selection criteria to AS and referral to treatment 
criteria than other cohorts like PRIAS or the Toronto cohort [7]. The JH cohort does contain 
mostly very-low risk men and no intermediate risk men.  We assume that given progression 
which is not dependent on JH data, the probability of referral to treatment is the same as for 
intermediate risk men, low-risk men and very low-risk men. (Except for volume progression 
which has higher probability of detection for low and intermediate risk men than for very low 
risk men). We also assume that all men whose progression is detected are referred to radical 
treatment, which may not happen in clinical practice [4].   
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Changes in the rate of clinical diagnosis could affect the cost-effectiveness of the intervention. 
We examined the effect of parametric uncertainty around the hazard of clinical diagnosis 
parameters in predicted QALYs and costs. We found that while the proportion of men treated 
may change significantly (Supporting Information Table 8) the cost per QALY did not vary 
substantially when we changed the values of the clinical diagnosis parameters by 20%. 
These results apply for the average US population. Populations at higher risk, for instance 
African-Americans, may need a more intensive schedule compared to their Caucasian peers, for 
the same age and disease group [10, 35]. Comorbidity level should also be taken into account 
when building a personalized AS biopsy schedule.   
From a safety perspective, we found that life years gained per each additional round of AS 
biopsies substantially decreases with age.  Importantly, men younger than 65 (or older men with 
intermediate risk disease) should be aware when deciding between AS and immediate treatment, 
that if they choose for AS, they may need to follow an intensive biopsy follow-up schedule, and 
that non-compliance with the biopsy schedule (i.e., implicitly choosing Conservative 
Management) could result in missing their opportunity for cure. 
While most clinical cohorts find that AS for low-risk men is safe, there is still some debate about 
the most optimal way to perform AS. In particular, it is not known, when should a person stop 
AS, if no progression is detected. We conclude that the AS protocol for younger low-risk men 
(55-65) and for older (65-75) intermediate-risk men could consist of at least 7 yearly biopsy 
rounds. For these men, immediate treatment should also be considered. For older (65-75) low-
risk men, AS is not effective compared to CM, after taking into account quality of life outcomes. 
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Therefore for these men, there is no need for AS with an intensive biopsy schedule or to remain 
for many years on AS.  
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Figure 1: An example of  a life history, where a man would experience clinical diagnosis 
and prostate cancer death in absence of screening, under different screening and post-
detection follow-up scenarios.*&  
 
* In “AS, One Biopsy” protocol, AS stops after one biopsy, in “AS, two biopsies” protocol, AS 
stops after two biopsies.  
& In this example we show the life history of a men who would be clinically diagnosed in 
absence of screening, and die from prostate cancer, but that could be saved by treating early. 
This men also experiences progression during AS, after the time of the first biopsy.   
 
 
 
Figure 2: Life Years Gained (LYG) and Overtreatment for Low-Risk Men (≤ T2a Gleason 
6, PSA <10) in AS by number of yearly biopsy rounds (1, 4, 7 and 10 rounds) compared 
with CM.  
 
*  All values are undiscounted. Biopsy frequency is yearly. The points in the figure are 
respectively after 1, 4, 7 and 10 biopsy rounds. AS denotes Active Surveillance, CM denotes 
Conservative Management.  
 
